See All Slides - tctmd.com

Slides

Presentation TCT 2019

Extreme Aortic Valve Complex Calcification Creating High Risk for TAVR Complications (Rupture or PVR): Case Presentation and Procedural Decision-Making

Presenter: Chiu Wong

September 27, 2019

Presentation TCT 2019

Critical Appraisal of Post-LAA Closure Pharmacology and Device-Related Thrombus

Presenter: Kishore Harjai

September 27, 2019

Debate: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients - Con: Beware of Ischemic Complications — Not Ready to Drop DAPT Yet!

Presentation TCT 2019

Con: Beware of Ischemic Complications — Not Ready to Drop DAPT Yet!

Presenter: Robert Byrne

September 27, 2019

Presentation TCT 2019

Noble: Extended Follow-Up and Substudies

Presenter: Evald Christiansen

September 27, 2019

Presentation TCT 2019

ARC Initiative for Heart Failure and Shock: HF ARC, Shock ARC, and More

Presenter: Christopher O'Connor

September 27, 2019

Presentation TCT 2019

Devices for Heart Failure: FDA Perspectives on Trial Designs and Endpoints

Presenter: Bram Zuckerman

September 27, 2019

Presentation TCT 2019

Device-Related Thrombus: Mechanisms, Management, and Implications for Device Design

Presenter: Simon Cheung-chi Lam

September 27, 2019

Presentation TCT 2019

TAVR and Concomitant Atrial Fibrillation: Case Presentation

Presenter: Fabian Nietlispach

September 27, 2019

Debate: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients - Pro: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients

Presentation TCT 2019

Pro: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients

Presenter: C. Michael Gibson

September 27, 2019

Presentation TCT 2019

Excel: Extended Follow-Up and Most Important Substudies

Presenter: Ori Ben-Yehuda

September 27, 2019

Advertisement

Slides

Extreme Aortic Valve Complex Calcification Creating High Risk for TAVR Complications (Rupture or PVR): Case Presentation and Procedural Decision-Making

Critical Appraisal of Post-LAA Closure Pharmacology and Device-Related Thrombus

Con: Beware of Ischemic Complications — Not Ready to Drop DAPT Yet!

Noble: Extended Follow-Up and Substudies

ARC Initiative for Heart Failure and Shock: HF ARC, Shock ARC, and More

Devices for Heart Failure: FDA Perspectives on Trial Designs and Endpoints

Device-Related Thrombus: Mechanisms, Management, and Implications for Device Design

TAVR and Concomitant Atrial Fibrillation: Case Presentation

Pro: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients

Excel: Extended Follow-Up and Most Important Substudies

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content